26 April 2022
Marker Therapeutics Announces Entry into Services Agreement with Wilson Wolf
HOUSTON, April 26, 2022 (GLOBE NEWSWIRE) -- -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the...
14 December 2021
Bio-Techne Announces Future Wilson Wolf Purchase Agreement
Bio-Techne announced it has entered into a purchase option agreement with Wilson Wolf Corporation, solidifying resources and support for ScaleReady...
10 November 2021
ScaleReady Launches Second Generation of Wilson Wolf G-Rex Product
The second generation G-Rex500M-CS improves on the materials and ergonomics of the original G-Rex while retaining the same cell expansion...
3 November 2021
Bio-Techne Releases First GMP-grade Cytokines from New GMP Facility
ScaleReady sources Bio-Techne cytokines because of their commitment to supplying the entire cell and gene therapy industry with GMP-grade, animal...
7 October 2021
CancerNetworks Interviews ScaleReady
Josh Ludgwig, Global Director of Commercial Operations at ScaleReady discusses what makes the company uniquely positioned to support manufacturing across...
1 October 2021
ScaleReady Joins the Alliance for Regenerative Medicine
As a member of The Alliance for Regenerative Medicine (ARM), ScaleReady committed to progressing regenerative medicine and advanced therapy manufacturing...
2 June 2021
ScaleReady hosts ISCT Symposium on Intelligent Scale-up
ScaleReady recruited a prestigious panel of cell therapy manufacturing experts to discuss their experiences and strategies for commercial scale up...
25 May 2021
RegMedNet interviews Josh Ludwig, Global Commercial Director
In this interview, Josh Ludwig, Global Director of Commercial Operations at ScaleReady, describes how a scalable, cost-effective and practical manufacturing...
6 January 2021
ScaleReady Launches
ScaleReady launches with the mission to make cell and gene therapy manufacturing practical and viable. Through a partnership between Bio-Techne,...
21 January 2020
Joint Venture formed by Bio-Techne, Fresenius Kabi, and Wilson Wolf
The joint venture focuses on providing scalable manufacturing technologies needed to develop and commercialize new cell and gene therapies. Each...